FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2327132015> ?p ?o ?g. }

• W2327132015 abstract "Background: Metastatic bone disease is a major cause of morbidity and mortality for breast cancer patients. Bisphosphonates (BP) have been shown to significantly delay the onset and frequency of skeletal related events (SREs), improve pain control and overall quality of life. Most patients receive intravenous BP every 3–4 weeks regardless of their individual risk for a SRE. This “one size fits all” strategy could expose those patients at a relatively low risk of SREs to an increased chance of adverse drug effects, as well as to the financial and quality of life burden of multiple visits to the cancer centre for treatments. This study aimed to assess whether IV BP can be safely given at reduced frequency. Methods: The primary objective of this study is to demonstrate in women with biochemically defined low-risk bone metastases that the administration of IV BP every 12 weeks is sufficient to maintain biochemical stability for one year. Eligibility criteria include; bone metastases from breast cancer, have received at least three months of regular 3–4 weekly IV BP, satisfactory renal function, adequate dental health, no systemic treatment change or recent SRE within 4 weeks of study entry. Low risk disease will be defined as serum CTx levels 600 ng/L measured at predefined time points (6, 12, 24, 36 and 48th). Secondary objectives are to evaluate the palliative benefit of 12-weekly IV BP therapy as reflected by occurrence of SREs, analgesic use, self-reported pain using the validated BP and FACT-BP questionnaires. Sample size was calculated at 68 patients. Given the small sample size, nonparametric Bootstrapping will be employed to calculate point estimates, standard deviations and 95% confidence intervals (CIs). An exploratory multivariable analysis will also be undertaken to determine baseline factors that were associated with patient9s maintaining their telopeptide levels in the low risk range. Conclusion: TRIUMPH opened in October 2010 and as of June 2011, has quickly accrued 54/68 patients (79%). This trial has the potential to allow lower risk women to receive less frequent dosing of bisphosphonates, thus improving their quality of life with less cancer center visits and reducing their chance of drug induced adverse events. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT1-01-02." @default.
• W2327132015 created "2016-06-24" @default.
• W2327132015 creator A5020776031 @default.
• W2327132015 creator A5046359837 @default.
• W2327132015 creator A5052074115 @default.
• W2327132015 creator A5055430046 @default.
• W2327132015 creator A5067907033 @default.
• W2327132015 creator A5070641975 @default.
• W2327132015 creator A5070650433 @default.
• W2327132015 creator A5074500372 @default.
• W2327132015 creator A5078386925 @default.
• W2327132015 creator A5079428114 @default.
• W2327132015 creator A5083050158 @default.
• W2327132015 creator A5089213464 @default.
• W2327132015 date "2011-12-15" @default.
• W2327132015 modified "2023-09-26" @default.
• W2327132015 title "OT1-01-02: A Multicentre Study Assessing 12-Weekly Intravenous Bisphosphonate Therapy in Women with Low Risk Bone Metastases from Breast Cancer – The TRIUMPH Trial." @default.
• W2327132015 doi "https://doi.org/10.1158/0008-5472.sabcs11-ot1-01-02" @default.
• W2327132015 hasPublicationYear "2011" @default.
• W2327132015 type Work @default.
• W2327132015 sameAs 2327132015 @default.
• W2327132015 citedByCount "0" @default.
• W2327132015 crossrefType "proceedings-article" @default.
• W2327132015 hasAuthorship W2327132015A5020776031 @default.
• W2327132015 hasAuthorship W2327132015A5046359837 @default.
• W2327132015 hasAuthorship W2327132015A5052074115 @default.
• W2327132015 hasAuthorship W2327132015A5055430046 @default.
• W2327132015 hasAuthorship W2327132015A5067907033 @default.
• W2327132015 hasAuthorship W2327132015A5070641975 @default.
• W2327132015 hasAuthorship W2327132015A5070650433 @default.
• W2327132015 hasAuthorship W2327132015A5074500372 @default.
• W2327132015 hasAuthorship W2327132015A5078386925 @default.
• W2327132015 hasAuthorship W2327132015A5079428114 @default.
• W2327132015 hasAuthorship W2327132015A5083050158 @default.
• W2327132015 hasAuthorship W2327132015A5089213464 @default.
• W2327132015 hasConcept C121608353 @default.
• W2327132015 hasConcept C126322002 @default.
• W2327132015 hasConcept C141071460 @default.
• W2327132015 hasConcept C143998085 @default.
• W2327132015 hasConcept C159110408 @default.
• W2327132015 hasConcept C197934379 @default.
• W2327132015 hasConcept C2776139714 @default.
• W2327132015 hasConcept C2776541429 @default.
• W2327132015 hasConcept C2777251235 @default.
• W2327132015 hasConcept C2779951463 @default.
• W2327132015 hasConcept C530470458 @default.
• W2327132015 hasConcept C71924100 @default.
• W2327132015 hasConceptScore W2327132015C121608353 @default.
• W2327132015 hasConceptScore W2327132015C126322002 @default.
• W2327132015 hasConceptScore W2327132015C141071460 @default.
• W2327132015 hasConceptScore W2327132015C143998085 @default.
• W2327132015 hasConceptScore W2327132015C159110408 @default.
• W2327132015 hasConceptScore W2327132015C197934379 @default.
• W2327132015 hasConceptScore W2327132015C2776139714 @default.
• W2327132015 hasConceptScore W2327132015C2776541429 @default.
• W2327132015 hasConceptScore W2327132015C2777251235 @default.
• W2327132015 hasConceptScore W2327132015C2779951463 @default.
• W2327132015 hasConceptScore W2327132015C530470458 @default.
• W2327132015 hasConceptScore W2327132015C71924100 @default.
• W2327132015 hasLocation W23271320151 @default.
• W2327132015 hasOpenAccess W2327132015 @default.
• W2327132015 hasPrimaryLocation W23271320151 @default.
• W2327132015 hasRelatedWork W1984805365 @default.
• W2327132015 hasRelatedWork W2011317885 @default.
• W2327132015 hasRelatedWork W2022225449 @default.
• W2327132015 hasRelatedWork W2087216581 @default.
• W2327132015 hasRelatedWork W2130748105 @default.
• W2327132015 hasRelatedWork W2178842021 @default.
• W2327132015 hasRelatedWork W2240569034 @default.
• W2327132015 hasRelatedWork W2410407484 @default.
• W2327132015 hasRelatedWork W2415962728 @default.
• W2327132015 hasRelatedWork W2417467422 @default.
• W2327132015 hasRelatedWork W2592468061 @default.
• W2327132015 hasRelatedWork W2618592599 @default.
• W2327132015 hasRelatedWork W2751628694 @default.
• W2327132015 hasRelatedWork W2756398933 @default.
• W2327132015 hasRelatedWork W2758288894 @default.
• W2327132015 hasRelatedWork W2910545790 @default.
• W2327132015 hasRelatedWork W2944681258 @default.
• W2327132015 hasRelatedWork W3033981055 @default.
• W2327132015 hasRelatedWork W3087307098 @default.
• W2327132015 hasRelatedWork W2739523608 @default.
• W2327132015 isParatext "false" @default.
• W2327132015 isRetracted "false" @default.
• W2327132015 magId "2327132015" @default.
• W2327132015 workType "article" @default.